- Home
- Companies
- montenegro
- tumor microenvironment
Refine by
Tumor Microenvironment Suppliers Serving Montenegro
30 companies found
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
based inCounty of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Two transgenes: Producing a secreted CD40 agonist monoclonal antibody. Currently in clinical trials in the US and UK. ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
based inParis, FRANCE
Inovarion is a research center in Life Sciences which has established itself in a few years as a key player in research and development in France. Through its talents, the Inovarion research center develops in-house research projects and guides its ...
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The ...
based inSuwon, SOUTH KOREA
Onegene Biotechnology develops transformative therapeutics for the chronic and complex diseases. Our UniStac platform allows rationale-based design of multispecific drug in true plug-and-play ...
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics’ latest proprietary ACTengine® manufacturing processes are designed to generate cell product candidates within a short manufacturing window and deliver highly proliferative T cells, with the capability to infiltrate the ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and another domain that binds to an extracellular molecule from tumoral microenvironment. ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
based inMarseille Cedex 9, FRANCE
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our ...
Immunogram, Veracyte’s advanced analytics platform, integrates multi-omic data sets and analyzes them into a single per patient view of key biomarker signatures, specific to their own Tumor ...
based inKöln, GERMANY
Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management. Singleron Biotechnologies is an innovative ...
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...